S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
The Stock That's Brining Lithium Back To America! (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
The Stock That's Brining Lithium Back To America! (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
The Stock That's Brining Lithium Back To America! (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
The Stock That's Brining Lithium Back To America! (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
The Stock That's Brining Lithium Back To America! (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
The Stock That's Brining Lithium Back To America! (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
The Stock That's Brining Lithium Back To America! (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
The Stock That's Brining Lithium Back To America! (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
NASDAQ:NMTR

9 Meters Biopharma (NMTR) Stock Forecast, Price & News

$0.75
+0.04 (+5.63%)
(As of 06/7/2023 ET)
Compare
Today's Range
$0.70
$0.78
50-Day Range
$0.66
$1.40
52-Week Range
$0.58
$13.20
Volume
87,997 shs
Average Volume
95,329 shs
Market Capitalization
$10.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.85

9 Meters Biopharma MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
5,790.0% Upside
$44.18 Price Target
Short Interest
Bearish
3.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.58mentions of 9 Meters Biopharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$11,011 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.89) to ($4.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.52 out of 5 stars

Medical Sector

883rd out of 981 stocks

Pharmaceutical Preparations Industry

420th out of 461 stocks


NMTR stock logo

About 9 Meters Biopharma (NASDAQ:NMTR) Stock

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.

Receive NMTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter.

NMTR Stock News Headlines

Temperato resigns as CEO of Raleigh drugmaker
This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
9 Meters Biopharma (NASDAQ: NMTR)
This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
NMTR - 9 Meters Biopharma, Inc.
Why this Raleigh pharma just cut half its workforce
See More Headlines

NMTR Price History

NMTR Company Calendar

Last Earnings
11/15/2021
Today
6/07/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NMTR
Fax
N/A
Employees
21
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$44.18
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$1.70
Forecasted Upside/Downside
+2,680.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-43,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.19 per share

Miscellaneous

Free Float
13,992,000
Market Cap
$10.76 million
Optionable
Optionable
Beta
1.36

Key Executives

  • John TemperatoJohn Temperato
    President, Chief Executive Officer & Director
  • Sireesh Appajosyula
    SVP-Corporate Development & Operations
  • Bethany L. Sensenig
    Chief Financial Officer
  • Patrick H. Griffin
    Chief Medical Officer
  • Nir Barak
    Senior Vice President-Scientific Affairs













NMTR Stock - Frequently Asked Questions

Should I buy or sell 9 Meters Biopharma stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NMTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NMTR, but not buy additional shares or sell existing shares.
View NMTR analyst ratings
or view top-rated stocks.

What is 9 Meters Biopharma's stock price forecast for 2023?

6 Wall Street analysts have issued 12-month price targets for 9 Meters Biopharma's shares. Their NMTR share price forecasts range from $1.70 to $100.00. On average, they predict the company's stock price to reach $44.18 in the next twelve months. This suggests a possible upside of 5,790.0% from the stock's current price.
View analysts price targets for NMTR
or view top-rated stocks among Wall Street analysts.

How have NMTR shares performed in 2023?

9 Meters Biopharma's stock was trading at $1.26 at the beginning of 2023. Since then, NMTR stock has decreased by 40.5% and is now trading at $0.75.
View the best growth stocks for 2023 here
.

When is 9 Meters Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our NMTR earnings forecast
.

How were 9 Meters Biopharma's earnings last quarter?

9 Meters Biopharma, Inc. (NASDAQ:NMTR) released its quarterly earnings results on Monday, November, 15th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.26.

When did 9 Meters Biopharma's stock split?

9 Meters Biopharma's stock reverse split on Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of 9 Meters Biopharma own?
What is 9 Meters Biopharma's stock symbol?

9 Meters Biopharma trades on the NASDAQ under the ticker symbol "NMTR."

Who are 9 Meters Biopharma's major shareholders?

9 Meters Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Sabby Management LLC (7.70%), CIBC Asset Management Inc (0.23%), Susquehanna International Group LLP (0.00%) and HRT Financial LP (0.13%). Insiders that own company stock include Bethany Sensenig, Edward J Sitar, Israel Gp Ltd Orbimed, John Temperato, Mark A Sirgo and Michael T Constantino.
View institutional ownership trends
.

How do I buy shares of 9 Meters Biopharma?

Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 9 Meters Biopharma's stock price today?

One share of NMTR stock can currently be purchased for approximately $0.75.

How much money does 9 Meters Biopharma make?

9 Meters Biopharma (NASDAQ:NMTR) has a market capitalization of $10.76 million. The company earns $-43,770,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis.

How can I contact 9 Meters Biopharma?

9 Meters Biopharma's mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The official website for the company is www.9meters.com. The company can be reached via phone at (919) 275-1933 or via email at investor-relations@9meters.com.

This page (NASDAQ:NMTR) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -